Some of the regulatory mechanisms of cyclic adenosine monophosphate (AMP) production in human brain tumors were investigated by assessing both cyclic AMP levels and adenyl cyclase activity. A large disparity was found between the levels of cyclic AMP of normal brain and brain-tumor tissue. Cyclic AMP levels were much lower in brain tumors (25.8 pmoles (picomoles)/mg protein) than in normal brain (98.8 pmoles/mg protein). These studies also show that the abnormally low levels of cyclic AMP in tumors parallel those of adenyl cyclase. The mean adenyi cyclase activity of brain tissue was found to be 111.0 pmoles of cyclic AMP/min/mg protein, while that of the tumor was only 23.0 pmoles/min/mg protein. Levels of cyclic AMP and adenyl cyclase activity were inversely related to the degree of malignancy. Attempts to stimulate adenyl cyclase in homogenates of human brain and brain tumors resulted in a similar response in both tissues. Norepinephrine was the most effective stimulant and produced a two-to threefold increase in cyclic AMP production, while histamine had no effect. It is concluded that one of the factors governing tumor growth may be a defect in the adenyl cyclase system.
C
YCLIC adenosine 3',5' monophosphate (AMP) has been implicated in a variety of physiological functions, including its ability to stimulate cell differentiation. There is much evidence suggesting that this nucleotide plays an important role in the regulation of cellular growth. A number of studies 1,7-9,~2.1',2~ have shown that exogenous cyclic AMP or its derivatives can influence the growth and morphology of a number of cultured cell lines inducing changes from undifferentiated malignant to more benign growth characteristics. An in vivo inhibition of subcutaneously inoculated Walker carcinoma cells 1~ and more recently * of two hormone-dependent mammary tumors in the rat has also been reported.
In accordance with these findings, several early papers e,ls,16,21 and a more recent one by Anderson and Pastan 2 reported that cyclic AMP concentration in transformed cells is lower than in comparable normal cells and that malignant transformation is associated with low levels of cyclic AMP.
Most of these data, however, were obtained with laboratory animals or cultured cell lines and from autopsy material, which is inadequate due to the rapid alterations that occur in the substances post mortem. Little is yet known about the cyclic AMP system in the human brain and especially in human brain tumors. We have therefore extended these studies and investigated some of the regulatory mechanisms of cyclic AMP production in human CNS tumors. Since cyclic AMP appears to control to some extent the expression of malignancy in a cell population, it was of interest to investigate levels and factors governing the accumulation of this nucleotide in these tissues as the results might help establish a new approach to the chemotherapy of brain tumors. This paper describes the results of these investigations.
Materials and Methods

Human Specimens
Brain-tumor specimens obtained during surgery were rapidly removed and immediately frozen in liquid nitrogen (LN~). Where portions of the uninvolved brain had to be resected for tumor exposure, a specimen of brain tissue was likewise removed and immediately frozen. All frozen tissues were stored in LN~ at -70 ~ C until needed for analysis.
Procedures
Sample Preparation. Frozen tissue was pulverized in a mortar and pestle precooled over dry ice, then weighed, homogenized with 20 volumes of 6% ice-cold trichloroacetic acid, and centrifuged for 10 minutes at 3500 rpm to remove the precipitate. The supernatant was washed three times with eight volumes of water-saturated ether after the addition of an appropriate volume of 0.1 N HC1. Small aliquots of the supernatant were evaporated to dryness under a stream of nitrogen and stored at -12 ~ C until needed for cyclic AMP determination.
Cyclic AMP Determination. Cyclic AMP* was assayed by a modification of the direct binding isotope dilution method of Gilman? A rat brain protein kinase (prepared in our laboratory as described by Kuo and Greengard 11 through the ammonium sulfate precipitation step) was used as the binding protein. Bovine serum albumin (10 mg/ml) was substituted for the protein kinase inhibitor and SHcAMPt of higher specific radioactivity, 37.7 Ci/mmole, was used. Adenyl Cyclase Determination. Adenyl cyclase activity was determined in the crude tissue homogenates and assayed as follows: tissue homogenates were prepared at 1:50 dilution with 2 mM Tris-HC1 buffer, pH 7.4. The standard incubation mixture in a final volume of 200 #1 consisted of the following: 80 mM Tris-HC1 buffer, pH 7.4, containing 4 mM MgSO4, 10 mM theophylline, and 2 mM adenosine triphosphate (ATP).w The reaction was initiated by the addition of the enzyme (that is, 50 #1 of the tissue homogenate) and carried out at 30 ~ C for 6 minutes. The enzymatic reaction was linear only up to 6 minutes of incubation (Fig. 1) . The reaction was stopped by placing the tubes in a boiling water bath for 5 minutes. Following centrifugation at 3500 rpm, the supernatant layer was separated and stored frozen at -12 ~ C until needed for analysis of cyclic AMP content. For each sample, a test and a control were set in duplicate. In the controls the substrate (ATP) was added after the enzyme had been denatured by boiling. The enzyme activity was calculated as the difference between the test and the control and When the response of tissue adenyl cyclase to stimuli was to be tested, brain-or tumortissue homogenates were incubated in the presence or absence of potential stimulants. These agents were directly added to the reaction mixture at concentrations ranging from 1.6 X 10-4M for epinephrine, 5 X 10-~M for norepinephrine and histamine,* 28 X 10-4M for the prostaglandins,t and 8 X 10-SM for sodium fluoride (NaF).
Protein was determined by the procedure of Lowry, et al., TM using bovine serum albumin as a standard.
Results
Cyclic AMP levels were measured in a total of 23 human brain tumor tissue, eight cerebral cortex, and three cerebellum specimens. As shown in Table 1 , the intracellular levels of cyclic AMP in the tumors were considerably lower than those of the brain. Cyclic AMP concentrations in the cerebral tissue ranged from 78 to 116 pmoles/mg protein with a mean of 98. (Table 2) . Therefore, these data would appear to substantiate the basic hypothesis that the level of cyclic AMP is inversely related to the degree of malignancy of the neoplasm. In our findings, the exceptions to this concept were a solitary chromophobe adenoma, which had quite a low cyclic AMP level, and a group of four metastatic carcinomas with a mean value of 36.4 pmoles/mg protein.
A similar pattern was observed when the cyclic AMP generating system, that is, the adenyl cyclase activity of these tumors was investigated. Tumors have considerably less adenyl cyclase than brain tissue (Table 3) . Under the same experimental conditions, the mean adenyl cyclase activity in the brain was found to be 1 11 pmoles of cyclic AMP/min/mg protein, while that of the tumor was only 23 pmoles/min/mg protein.
The difference of the means between brain and tumor was 88 with a range of 55 to 121 pmoles/min/mg protein, p < 0.05.
Low enzyme activity in the tumors is translated into an equivalent low concentration of cyclic AMP. Conversely, the high cyclase activity in the brain is reflected in the high levels of cyclic AMP.
Previous studies 18 have indicated that the primary distinguishing feature of adenyl cyclase in different tissue is its pattern of responsiveness to hormones or other drugs. In anticipation that the specificity of responsiveness of the enzyme might be different in tumors as compared to brain tissue, we studied the effect of a variety of drugs on the adenyl cyclase activity of both tissues. However, although the basal activity of the adenyl cyclase of the tumor preparation was markedly lower than that of the brain, its response to stimuli was relatively similar to that of normal tissue (See Table 4 ). Norepinephrine produced a two-to threefold increase in cyclic AMP production; epinephrine:~ was less effective, while the prostaglandins E1 and E2 and histamine produced little or no effect. The enzyme preparations of both tissues were consistently stimulated by NaF, which is known to stimulate adenyl cyclase activity in various tissues of other animals.
Calcium (Ca ++ ) has been generally regarded as an inhibitor of adenyl cyclase. However, low concentrations (micromolar range) have been reported to increase the accumulation of cyclic AMP in intact cells and to stimulate adenyl cyclaseY s Thus, the Ca ++ sensitivity of the broken-cell preparations from tumor tissue was investigated by studying the effect of EGTA (ethylene glycol-bis (B-aminomethyl ether) N-N tetra acetic acid) on the cyclase activity. Tissues were homogenized in 2 mM Tris-HCl buffer containing 8 mM EGTA and assayed for adenyl cyclase as described in Methods. As shown in Fig. 2 , EGTA produced a 70% inhibition of the enzymatic activity.
Discussion
Numerous reports s,xS,17al and more recently studies by Anderson and Pastan 2 have indicated that transformed fibroblasts have low levels of cyclic AMP and that some abnormal properties of these cells are due to the low levels of the cyclic nucleotide. Our data substantiate these findings and indicate The comparatively higher levels of cyclic AMP in the four metastatic carcinomas may be explained by the fact that these neoplasms, because of their metastatic nature, could have a mixed-cell population (normal and malignant cells) and thus the cyclic AMP values obtained represent those of the composite-cell types.
Furthermore, the present studies show that the abnormally low levels of cyclic AMP in tumors parallel those of adenyl cyclase. These results are also in agreement with previous systems such as virally induced or transformed cells and indicate that brain-tumor cells likewise contain less adenyl cyclase activity than the parent normal tissue.
Under normal conditions, the balance between the enzyme systems, adenyl cyclase and phosphodiesterase, plays an essential role in the regulation of the intracellular concentration of cyclic AMP. The low levels of cyclic AMP in tumors could thus be the result of: 1) a decreased synthesis due to a reduction in the adenyl cyclase; or 2) an increased hydrolysis from an elevation in the phosphodiesterase activity. Our findings indicate that one of the rate-limiting factors of cyclic AMP production in brain tumor is, in fact, the reduction in adenyl cyclase.
The response of tumor tissue adenyl cyclase to the various drugs, although limited, was not markedly different from that of normal brain tissue to these agents. The results of these drug studies suggest that the catalytic site of the adenyl cyclase, which is stimulated by NaF, is apparently unaltered in neoplasms. There may be, however, some structural alterations in the receptor sites with which the various hormones and prostaglandins interact. Adenyl cyclase is located in the plasma membrane where changes in transformation are frequently observed. It is thus conceivable that malignancy produces changes in the plasma membrane that can either alter the regulatory properties of the cyclase system or reduce the available receptor sites, thereby decreasing the cyclase activity.
Moreover, our data show that the effect of the neurohormones on the adenyl cyclase of human tissue homogenates was of a lesser magnitude than that reported on either rat or human brain slices. However, it has been a general finding that broken-cell preparations are less sensitive to hormonal stimulation than intact-cell preparations. Apparently, there is a factor that is released during hormone stimulation of these slices which in turn activates the adenyl cyclase. Could this factor be also released during homogenization? The results of a number of investigations point in that direction. In fact, several investigators 2,~~ have shown the presence of an activator of adenyl cyclase in the supernatant fraction of tissue homogenates which is released during homogenization. Thus, they speculated that homogenization (by releasing this activator) may lead to a possible increase in the basal rate of adenylate cyclase in tissue homogenates relative to the rate in intact cell of tissue slices. Consequently, one cannot show any further appreciable activation by other agents; thus the action of neurohormones becomes much less evident. Since no direct and meaningful comparison of adenylate cyclase in tissue slices and homogenates is currently possible, the reason for the discrepancy in responses between slices and homogenates is still a matter of speculation.
There was essentially no alteration in the sensitivity of the tumor adenyl cyclase for Ca ++ . The enzyme was similar to brain adenyl cyclase from other species in that it was inhibited by EGTA.
Due to the cellular heterogeneity of brain tissue, a direct comparison of the cyclic AMP system between normal brain and braintumor tissues may be difficult. Naturally, one must be wary of the cellular complexity of brain tissue in interpreting the results of this investigation. However, an important fact emerging from these findings is that all tumors studied, independent of their cellular origin, have significantly lower levels of cyclic AMP and adenyl cyclase activity than normal brain.
These findings, coupled with previous reports of tumor-growth suppression by exogenous cyclic AMP, its derivatives, and also by stimulators of adenyl cyclase, suggest that one of the factors governing tumor growth may be a defect in the adenyl cyclase system. Further definition of the cyclic AMP regulating system may thus open new avenues for treatment of brain tumors as well as other neoplasms, and therefore deserves further attention. Such studies are already in progress in our laboratory and will be reported shortly.
